Emotional and social experiences with fibrosis medications
Part of Lungs & breathing clinical trials.
This study looks at how people with pulmonary fibrosis feel emotionally and socially while taking antifibrotic medications like nintedanib or pirfenidone. It aims to understand the real-world impact of these treatments on daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of pulmonary fibrosis called IPF and are 40 or older
- You have another type called PPF and are 18 or older
- You have been taking nintedanib or pirfenidone for at least 4 weeks
- You can fill out a questionnaire on your own
- You have not taken part in certain other studies or treatments (likely checked during pre-screening)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how patients with pulmonary fibrosis (lung scarring) make decisions about stopping or continuing anti-fibrosis medications, especially if they have had side effects. It may help doctors and patients understand the best treatment choices.
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
This trial tests an oral medicine called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to see if the drug can help slow the disease. You may qualify if you are 40 or older, have a confirmed IPF diagnosis with certain lung function levels, and are either on a stable dose of standard IPF meds or not taking them.
This trial tests a new medicine called HSK44459 for people with progressive pulmonary fibrosis (PPF). It aims to see if the drug can help slow lung damage and improve breathing. You may join if you are not taking certain other fibrosis drugs or have been on a stable dose for at least 12 weeks.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.